1. (valid email required)
 

cforms contact form by delicious:days

Archive for December, 2010

TRIO™ multispectral imaging system launched for multi-analyte investigation in tissue

New Imaging Technology Delivers Affordable Brightfield and Fluorescence Multicolor Protein Analysis

Nuance TRIO

Woburn, Massachusetts – November 9, 2010 – Cambridge Research & Instrumentation, Inc. (CRi), a leader in multicolor imaging solutions for preclinical and clinical research, today announced the newest addition to the award-winning Nuance™ multispectral imaging product family for multicolor tissue and cell-based imaging. The TRIO™ system is compact, multipurpose and affordable, offering a simplified interface and versatile design to fit any microscope with a camera-mount. This newest offering strengthens CRi’s objective to offer a comprehensive and intuitive solution that enables customers from basic research through pre-clinical drug discovery to reveal correlations between protein expression in intact tissue and clinical outcomes.

Multi-analyte detection from intact tissue and cells often poses a challenge since overlapping signals and the sample’s own background autofluorescence can mask critical information. TRIO’s multispectral imaging technology found in all of CRi’s multispectral systems effectively unmixes overlapping labels in fluorescence or brightfield samples. It has a new easy-to-use software interface designed to preclude the need to have expert-level knowledge of multispectral imaging, a common hurdle that faces many scientists who want to be able to image multiple markers from a single tissue sample. TRIO’s interface ensures that data can be obtained in a matter of minutes.

“Detecting multiple markers in intact tissue sections and in individual tumor cells is an important component of targeted drug and molecular diagnostic development,” said Darren Lee, Vice President of Marketing at CRi. “We understand the hurdles associated with doing multilabel imaging, including the complexities of interpreting multispectral data. We are very excited about TRIO because it makes multicolor imaging of tissue and cells much easier and more accessible to the mainstream researcher.” Lee added, “TRIO fits nicely within our core strategies, providing solutions that help address one of the biggest challenges facing scientists: trying to understand the mechanisms behind disease.”

About CRi, Inc.

Cambridge Research & Instrumentation (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ and TRIO™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

Contact:

Cathy Boutin, Marketing Manager

Cambridge Research & Instrumentation, Inc. (CRi)

Tel. 781-935-9099

Email: cboutin@cri-inc.com

TRIO™ multispectral imaging system launched for multi-analyte investigation in tissue
Woburn, Massachusetts - November 9, 2010 - Cambridge Research & Instrumentation, Inc. (CRi), a leader in multicolor imaging solutions for preclinical and clinical research, today announced the newest addition to the award-winning Nuance™ multispectral imaging product family for multicolor tissue and cell-based imaging. The TRIO™ system is compact, multipurpose and affordable, offering a simplified interface and versatile design to fit any microscope with a camera-mount. »

CRi’s Maestro Dynamic™ in-vivo imaging system named as Top 10 Innovation of 2010 by The Scientist magazine

All-optical kinetic imaging system generates real-time images of biodistribution and biological activity in small, live animals

Woburn, Massachusetts – December 1, 2010 – Cambridge Research & Instrumentation, Inc. (CRi), a leader in multicolor imaging solutions for preclinical and clinical research, today announced the latest addition to an already impressive number of awards. The Scientist, Faculty of 1000’s magazine of the life sciences, announced the winners of the “Top 10 Innovations of 2010”, among them CRi’s Maestro Dynamic™ in-vivo imaging system.

Watching drugs or biologics pulse through a patient in real time usually takes expensive equipment such as a PET and/or CT scanner. For in vivo mouse studies on tight budgets researchers commonly bind a fluorescent marker to the compound of interest, and take a fluorescence snapshot. The natural background fluorescence of the entire mouse—which makes it hard to distinguish the target from normal tissue—is then subtracted away to sharpen the image. But subtracting background fluorescence in a live movie proved challenging. So the scientists and engineers at Cambridge Research & Instrumentation Inc. (CRI) took a page from PET scan technology: using the compound’s pharmacokinetics—the rate at which the drug is absorbed, circulated, and excreted—they improved the resolution by compensating for the background at every time point.

The technology, called Maestro Dynamic, could be especially useful for tracking how long cancer drugs remain at their target before being metabolized and/or excreted. Normally, to obtain data about drug accumulation in organs or tumors, one would sacrifice a cohort of mice every hour or two over the course of a day. By continually collecting data in real time, says James Mansfield, director of the company’s multispectral imaging systems, the number of mice needed could be reduced from around 100–200 to about 10.

About CRi, Inc.

Cambridge Research & Instrumentation (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ and TRIO™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

Contact:

Cathy Boutin, Marketing Manager

Cambridge Research & Instrumentation, Inc. (CRi)

Tel. 781-935-9099

Email: cboutin@cri-inc.com

CRi’s Maestro Dynamic™ in-vivo imaging system named as Top 10 Innovation of 2010 by The Scientist magazine
Woburn, Massachusetts - December 1, 2010 - Cambridge Research & Instrumentation, Inc. (CRi), a leader in multicolor imaging solutions for preclinical and clinical research, today announced the latest addition to an already impressive number of awards. The Scientist, Faculty of 1000’s magazine of the life sciences, announced the winners of the “Top 10 Innovations of 2010”, among them CRi’s Maestro Dynamic™ in-vivo imaging system. »

Segue Manufacturing Services Expands Operations into Asia

Acquisition of Sanbor Interconnect bolsters Segue’s leadership in the OEM contract manufacturing space offering expertise in over molded cables and high volume assemblies

For Immediate Release

Lowell, Mass. November 29, 2010 Segue Manufacturing Services (Segue) has announced it has acquired Sanbor Interconnect in Xiamen, China. The acquisition includes a 55,000 sq. ft. manufacturing facility in Xiamen, China, and an engineering and sales office in Allentown, PA. With the expansion, Segue can offer its customers the cost benefits of off-shore manufacturing as well as additional manufacturing capabilities including “smart cable assemblies” that incorporate integrated circuits and over molding, and high-volume assemblies such as electronic sub-assemblies and box builds.

Segue Asia will benefit from Asia’s lower cost structures and manufacturing capabilities and is complemented by engineering and manufacturing facilities in the United States to ensure that Segue customers receive the best quality product at a cost competitive price. “More and more often our customers are competing in a global, competitive environment. To help our customers thrive, we now offer the benefits of offshore manufacturing with a local approach to customer service and support,” said Peter Frasso, President and CEO at Segue. “Sanbor has received quality awards by a number of Fortune 500 clients. Its quality systems and added capabilities will benefit our current customer base and offer us entrance into new markets and applications such as medical device, aviation, professional sound system and data communication.”

With the expansion, Segue provides the complete solution for complex electro-mechanical assemblies, specializing in manufacturing products that are low to medium volume with a high mix of options and new product introduction in the United States, to high-volume, complex assemblies in Asia. Both locations operate in a streamlined and controlled manufacturing environment through the application of lean manufacturing and JIT/Demand flow principles. To ensure quality products and services, both locations have quality systems that are certified to ISO 9001-2008, ISO 13485, ITAR registered, CE, UL and CSA compliant and certified to IPC 620-A-WHMA and IPCJ-STD-001. In addition, our Xiamen location is certified to TS16949:2009.

“Offshore manufacturing can only be successful if you have a relationship with your contract manufacturer that is built on trust, honesty, and, most importantly, communication,” adds Bill Roderick, Vice President at Segue. “At Segue, we offer the best of both worlds; the opportunity to take advantage of low-cost, off-shore manufacturing while strengthening partnerships and communicating with our offices here in the States.”

About Segue Manufacturing Services
Segue Manufacturing Services is a U.S. owned and operated, global contract manufacturer providing a portfolio of engineering services and manufacturing capabilities from sub-assembly level to complete end-to-end manufacturing in a lean manufacturing environment. We provide our customers a competitive edge through a comprehensive suite of cost-effective manufacturing that is unavailable from most regional contract manufacturers. From low-to-moderate volumes, high-mix production and new product introduction in the United States, we transition to high-volume, complex assemblies at our facility in Xiamen, China.
For more information about Segue Manufacturing Services, please visit at www.segue-mfg.com.

Segue Manufacturing Services Expands Operations into Asia
November 29, 2010 Lowell, Mass., - Segue Manufacturing Services (Segue) has announced it has acquired Sanbor Interconnect in Xiamen, China. The acquisition includes a 55,000 sq. ft. manufacturing facility in Xiamen, China, and an engineering and sales office in Allentown, PA. With the expansion, Segue can offer its customers the cost benefits of off-shore manufacturing as well as additional manufacturing capabilities including “smart cable assemblies” that incorporate integrated circuits and over molding, and high-volume assemblies such as electronic sub-assemblies and box builds. »

Latest News

Datawatch Self-Service Data Preparation Platform in High Demand in Healthcare Market

NWN Recognized in CRN Elite 150 For Managed IT Services and Placed on Managed Service Provider 500 List

Bigbelly Unveils Top 2016 Successes for Optimized Collections & Recycling Diversion

Southern California Edison Awards Cadmus MSA to Support Zero Net Energy Schools

» More News


Latest Newsletters

April 2017 – MCRC Announces a New Investment in Baynes Electric Supply

March 2017 – Mass Capital Announces a New Investment in Tri-Wire Engineering Solutions, Inc.

July 2016 – Mass Capital Announces a New Investment in The Cadmus Group, Inc.

» More Newsletters


Archives!